glp-1 agonists and inflammation in Cardiovascular Diseases: Mechanisms, Clinical Evidence, Emerging Therapies Cardiovascular Effects of Glucagon-Like Peptide-1

Weight loss drugs may be an option for you if you have obesity, which is defined as a body mass index (BMI) of 30 or higher

NASH, Non-alcoholic steatohepatitis

& Liu, K

In a randomized, placebo-controlled trial of semaglutide treatment, 62 % of adolescent participants in the semaglutide group achieved a loss of body weight of at least 10 %, with 37 % of subjects achieving weight reduction of at least 20 % [138,156]

Obesity is also a major driver of non-communicable diseases such as cardiovascular disease and some cancers

Kardie Tobb, DO, MS, FASPC, FACC, a boardcertified preventive cardiologist and the medical director for the Cone Health HeartCare Womens Heart Health and Cardio-Obstetrics Clinic, explains some of the most common reasons why GLP-1s may not deliver the results youre hoping for, including: You need a higher dose and have not yet reached a therapeutic dose as determined by your doctor High intake of liquid calories , including alcohol and ultra-processed foods Not getting enough protein , which can leave you persistently hungry and makes it harder to feel full Advanced diabetes or insulin resistance Taking other medications such as sulfonylureas, which lower blood sugar but can lead to weight gain Not adhering to your dosing schedule , such as inconsistent weekly injections or missed doses Differences in gut hormones or genetics And just because your GLP-1 isnt working immediately doesnt mean it wont work for you